Please login to the form below

Not currently logged in
Email:
Password:

bladder cancer

This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.

Positive first-line phase 3 results for Tecentriq

Positive first-line phase 3 results for Tecentriq

Hopes to extend use in bladder cancer. Roche has revealed that its blockbuster drug Tecentriq (atezolizumab) has met its co-primary endpoint in an ongoing study in bladder cancer, with hopes ... If Tecentriq can meet the secondary endpoints of the study

Latest news

  • New products help lift Roche outlook despite biosimilar onslaught New products help lift Roche outlook despite biosimilar onslaught

    from non-small cell lung cancer, another 20% from bladder cancer, and 5% from triple-negative breast cancer, its newest indication. ... Finally, the period also saw the approval of two new cancer treatments, Rozlytrek and  Polivy..

  • AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer AZ’s Imfinzi joins immunotherapy drive in small cell lung cancer

    Imfinzi is already approved as a second-line maintenance therapy for non-small cell lung cancer (NSCLC), which is more common than SCLC, as well as bladder cancer, with sales rocketing ... including new NSCLC settings and head and neck cancer – that

  • Merck claims key FDA okay for Bavencio in kidney cancer Merck claims key FDA okay for Bavencio in kidney cancer

    At least kidney cancer is a much larger market with upwards of 70, 000 new cases in the US every year, according to the American Cancer Society. ... Last year, Bavencio picked up another approval in second-line bladder cancer, but is having to compete

  • J&J’s targeted bladder cancer treatment gets US approval J&J’s targeted bladder cancer treatment gets US approval

    AstraZeneca also has an FGFR candidate in a phase 1b trial for bladder cancer. ... Although FGFR inhibitors have been developed for use within bladder cancer, the drugs’ use could be extended into earlier-stage cancers, further expanding its potential

  • CHMP recommends new Keytruda dosing schedule CHMP recommends new Keytruda dosing schedule

    It will be applied across all eight of Keytruda’s monotherapy indications in five tumour types, including non-small cell lung cancer (NSCLC), melanoma, bladder cancer, head and neck cancer and ... It made history by becoming the first FDA-approved drug

More from news
Approximately 20 fully matching, plus 98 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer  (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... drug and the risk of bladder cancer.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs).  . ... bladder cancer.

  • Achieving consensus

    Their joint aim: to facilitate uniform use of fluorescence cystoscopy in the diagnosis and follow up of bladder cancer, with the ultimate goal of improved care and better outcomes for patients. ... Despite widespread acceptance of the evidence for

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • New hires at Ferring, Flexion and Immunocore New hires at Ferring, Flexion and Immunocore

    It’s the first major appointment for Ferring in 2019, and the company says Opdyke will lead the potential commercial launch of its investigational gene therapy for bladder cancer patients in ... He said: “At the heart of cancer immunity is a T cell

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • A reflection of ESMO

    The objective for this congress is for HCPs to learn from physicians and scientists who present their research in prostate, bladder, and kidney cancer. ... highlighting the ground-breaking research in cancer care.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics